Finance Minister Nirmala Sitharaman is likely to strike a fine balance between being fiscally prudent and growth supportive when she presents her fourth straight budget on Tuesday, which is expected to have plans to boost spending to revive investment and create jobs. The Budget for the fiscal year starting April 1, 2022 is likely to raise spending on infrastructure to set the economy on a firmer footing. The stage for the Budget presentation was set by the Economic Survey stating that the government has the fiscal space to do more to support the economy that is forecast to grow at a healthy 8-8.5 per cent growth in the 2022-23 fiscal.
'Professors can teach even when they are 90 because they don't lose their skill with words. Go deeper and there's spirituality in it.'
Once stability returns to the secondary market, companies that have obtained approval from Sebi will start tapping the market.
Currently, 100 per cent FDI is permitted in brownfield pharma firms through clearance from the Foreign Investment Promotion Board.
Sun Pharma to retain these in most markets; US could be the exception, where the Ranbaxy name has taken a hit.
A key lesson for the pharmaceutical sector in this case is to not downplay the significant impact that regulatory non-compliance can have on operations.
The IPO rush will continue in September with two more companies Vijaya Diagnostic Centre and Ami Organics launching their initial share-sales on Wednesday to raise a total of Rs 2,465 crore. This comes after eight companies including Devyani International, Nuvoco Vistas Corporation and CarTrade Tech floated their initial share-sales last month to mobilise Rs 18,243 crore. So far in the current fiscal, a total of 20 companies have mopped up more than Rs 45,000 crore through IPOs. This is much higher than Rs 31,277 crore raised by 30 firms in the entire 2020-21.
Currently, the spend on R&D as a percentage of GDP is just 0.9%
Over the past year we have heard a lot about policy reforms to improve the ease of doing business in India.
Of the 23 companies, eight have raised funds after Shark Tank India.
Sun Pharmaceutical Industries will take a call on whether to shut Ranbaxy's troubled factories or make changes in the top management of the latter only after its $4-billion acquisition deal is complete.
The merger has fortified Sun Pharma's position.
The list includes Hindustan Unilever, Asian Paints and Bharti Airtel - firms that investors feel are most likely to come up with the next big innovation.
Globally, the SME business is among the fifth and sixth positions for Adobe.
If we are to realise the full potential of biologics' ability to improve people's health, it is essential to encourage public policy and support R&D.
The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.
While companies continue to face regulatory pressure leading to higher costs, they see an uptick from the launch of differentiated and high-margin products
Imports rose by 1.44 per cent to $43.44 billion in March 2019.
The 'Make in India' vision cannot survive in the long-term without concrete measures to build a concurrent 'Create in India' movement.
Services attract highest foreign direct investment, despite Make in India push.
The Crisil study covered 600 companies excluding financial services and oil companies, representing 71 per cent of the overall market capitalisation of India Inc.
A new logo, colour and tagline were unveiled last month.
Roadblocks ahead as these medicines could face new clinical tests, more scrutiny
Under the current administration, political attitudes toward IP seem to have improved.
Only 11 antibiotics in clinical trials have received qualified infectious disease product status from the US FDA, of which five are Wockhardt's drugs.
The disease could go down several paths. One possibility, the least likely, is that it will just disappear. The most likely is that it will have seasonal impact, says Devangshu Datta.
New government should consider reforming taxation rules.
India's IPR framework and enforcement were comparable to those in developed countries
Currently, Himalaya sells 250 products across the globe.
.jpg)
After a high-level meeting held on Friday chaired by Prime Minister Manmohan Singh, it has been decided that the Commerce and Industry would soon start a consultation process to address 'dangers inherent' in the current model of FDI in brownfield pharma units.
After spending considerable time and energy in remediation efforts in the wake of the US Food and Drug Administration's warning letter on compliance issues, the company's leadership has finally set out to bring the house in order.
Not just from the likes of Alibaba and Didi Chuxing, Indian startups saw a surge in Chinese funding from financial investors in 2019. This is a seven-fold jump from $459 million in 2016.
Ecotrail Personal Care, a start-up by sisters Mauli and Grishma Teli, is the only company in India that makes halal cosmetics
'India missed the software products revolution (and now is in danger of missing the platform revolution), complacent that we are the software experts of the world based on IT services prowess,' points out Rajeev Srinivasan.
Thailand expressed interest in the Indian defence industry and its experience and expertise in the field of defence R&D and production. Modi welcomed Thai investments in India in the potential areas under the 'Make in India' initiative, especially in the manufacturing sector, infrastructure development, tourism and hospitality facilities.
It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues
Top ten billionaires in India.
The council resisted intense pressure from the powerful manufacturing, pharma and other trade lobbies that have urged the Obama administration to enact punitive measures against India for a laundry list of alleged intellectual property and patent violations.
Can Nestle go beyond Maggi? While recovery in the March quarter has been led by the popular noodle brand, the company hopes for a different revenue mix in five years.
To ensure equal access to health care, the government must consider it in a holistic manner and improve all parameters.
